Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Translational relevance
Dendritic cell vaccination constitutes a promising novel immunotherapy in cancer. For optimal T cell induction it is crucial for the dendritic cells to interact with T cells in the lymph nodes. Although previous studies have shown that after intranodal administration more DCs spread throughout the lymphatic system as compared to intradermal administration, robust clinical trials comparing the different routes of administration are lacking.
Here, we directly compared the two routes of administration in 43 melanoma patients with locoregional lymph node metastases. We found that upon intradermal vaccination the induced T cells were more often able to recognize endogenously processed tumor antigens as compared to intranodal vaccination. Thus,
Introduction
Over the past decade vaccines consisting of autologous dendritic cells (DC) loaded with tumor antigens have proven to be safe and capable of inducing tumor antigen-specific immune responses in a substantial part of the vaccinated patients. However, clinical efficacy is still limited, underlining the necessity to further optimize different parameters such as DC subtype, DC maturation and activation status, and the route, dose and frequency of administration(1;2). We and others previously demonstrated that maturation of the DC is essential to develop their migratory capacity and their capacity to induce antigen-specific T cells (13) (14) (15) . In previous studies we showed that although the majority of DC remain localized at the injection site and are phagocytosed by macrophages, a small number migrates to the T cell areas within the lymph nodes. Within the lymph node, these DC associate with T cells and are capable of inducing antigen-specific T cell responses in vivo(16;17). The existence of circulating antigen-specific T cells after DC vaccination could be demonstrated in skin biopsies taken from delayed type hypersensitivity (DTH) reactions, indicating that vaccine-induced T cells are indeed capable of homing to sites where antigen is exposed by DC(5). Furthermore, the presence of such antigen-specific T cells at DTH sites clearly correlated with improved survival(5), demonstrating that skin biopsies taken from DTH sites are a representative compartment for immunomonitoring. intranodal and intradermal DC vaccine administration, to determine the effect of route of administration on the induction of immunological responses in melanoma patients with locoregional lymph node metastases.
Although true clinical benefit of low-dose IL-2 has not been unequivocally proven in melanoma(23-26), it has been suggested that low-dose IL-2 may enhance proliferation of antigen-specific T cells after DC vaccination (27;28) . Therefore, we also examined if concomitant treatment with low-dose IL-2 increases the efficacy of the DC vaccine.
Research. 
Materials and Methods

Study protocol and patient population
In this study, stage III and IV melanoma patients (according to American Joint Committee on Cancer criteria) who were scheduled for regional lymph node dissection with either curative or palliative intention were included. Additional inclusion criteria included HLA-A2.1 phenotype, melanoma expressing the melanoma-associated antigens gp100 and tyrosinase, and WHO performance status 0 or 1. Patients with brain metastases, serious concomitant disease or a history of a second malignancy were excluded. The study was approved by the Regional Review Board, and written informed consent was obtained from all patients. Clinical trial registration number is NCT00243594.
Patients received a DC vaccine via ID or IN injection, either with or without systemically administered IL-2.
The first 20 patients were assigned to either the IN+IL-2 or ID+IL-2 arm in an alternating manner, the next cohort of patients was assigned to either the IN without IL-2 or the ID without IL-2 arm in an alternating manner. Assignment was performed by IJMdV who had no knowledge about the clinical characteristics of the patients. IN vaccination was performed in a clinically tumor-free lymph node under ultrasound guidance. ID vaccination was performed at 5-10 cm distal from a (preferably inguinal) clinically tumor-free lymph node, by clinicians with extensive experience with the procedure (WJL, EHJGA, CJAP). Since the first vaccination was administered one day before regional lymph node dissection, presumably a significant benefit to the patient could not be expected. For this reason, the first vaccination always consisted of an injection of radionuclide-labeled, but not peptide-pulsed and not KLH-loaded DC on the side of the lymph node dissection, and an injection of peptide-pulsed DC on the contra-lateral side. The latter vaccine could be radionuclide-labeled or not. The DC vaccine consisted of autologous mature DC pulsed with gp100 and tyrosinase peptides and keyhole limpet hemocyanin (KLH). Patients received one cycle consisting of four DC vaccinations administered at a biweekly interval. IL-2 was administered by subcutaneous injections (at 9 MIU) once daily for one week starting three days after each DC vaccination.
Twenty four to 48 hours after the first vaccination a radical lymph node dissection was performed. One to two weeks after the fourth vaccination a DTH test was performed. All patients who remained free of disease progression after the first vaccination cycle were eligible for two maintenance cycles, each at 6-Research. figure   1 ). Patients were considered evaluable when they had completed the first vaccination cycle. Vaccinespecific immune response was the primary endpoint. Clinical response was a secondary endpoint.
Progression-free survival was defined as the time from apheresis to recurrence (for stage III patients) or progression (for stage IV patients).
DC preparation and characterization
KLH-loaded DC were generated from peripheral-blood mononuclear cells (PBMC) and matured with autologous monocyte-conditioned medium containing prostaglandin E 2 (10 µg/ml; Pharmacia & Upjohn, Puurs, Belgium) and recombinant tumor necrosis factor alpha (10 ng/ml; provided by Dr G. Adolf, Bender
Wien, Vienna, Austria), as described (29;30) . This procedure gave rise to mature DC meeting the release criteria (29) .
Peptide pulsing
DC were pulsed with the HLA class I gp100-derived peptides gp100 154-167 and gp100 [280] [281] [282] [283] [284] [285] [286] [287] [288] , and the tyrosinase-derived peptide tyrosinase [369] [370] [371] [372] [373] [374] [375] [376] (31) (32) (33) . Peptide pulsing was performed as described(13), and cells were resuspended in 0.1 ml for injection.
DC migration
DC migration node was measured after the first vaccination by scintigraphic imaging as described(16). In-labeled dendritic cells that had migrated from the injection depot to following lymph nodes after 2 days(16). Patients simultaneously received peptide-loaded DC in a contralateral clinically tumor-free lymph node, which was not to be resected.
Delayed type hypersensitivity test
Previously, we have developed a monitoring tool to assess T cell responses following vaccination, using DTH-infiltrated T cells(13). We have demonstrated that the presence of DTH-infiltrated vaccine-specific T cells correlates with clinical outcome(5). In this study, DTH skin tests were performed approximately two weeks after the fourth vaccination as described previously(5). DC pulsed with gp100 and tyrosinase peptides (2 to 10x10 6 DC each) were injected ID in the skin of the back of the patient at four different sites.
The maximum diameter of induration was measured after 48 hours. From positive DTH sites (> 2 mm), punch biopsies (6 mm) were obtained. Half of the biopsy was cryopreserved and the other part was manually cut and cultured in RPMI 1640 containing 7% human serum and IL-2 (100 U/ml). Every 7 days, half of the medium was replaced by fresh medium containing HS and IL-2. After 2 to 4 weeks of culturing, T cells were tested.
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Antigen and tumor recognition
Antigen recognition was determined by the production of cytokines or cytotoxic activity of DTH-derived cells in response to T2 cells pulsed with the indicated peptides or BLM (HLA-A2.1-positive melanoma cell line without endogenous expression of gp100 or tyrosinase), transfected with control antigen G250, gp100
or tyrosinase, or an allogeneic HLA-A2.1-positive, gp100-and tyrosinase-positive tumor cell line (MEL624)
were measured. Cytotoxic activity was measured using a chromium release assay (35) . Cytokine production was measured in supernatants after 16 hours of coculture by cytometric bead array (Th1/Th2
Cytokine CBA1; BD Pharmingen). The reason we used three different types of target cells is because it has been shown previously that peptide-induced T cells not necessarily also recognize the corresponding endogenously processed antigen (36) .
FOXP3 staining
Statistical analysis
Differences between groups were evaluated using ANOVA (KLH-specific proliferation and -antibodies, 
Results
Patient characteristics and treatment
Of a total of 47 patients enrolled in this study four patients were excluded from the analysis; two patients due to rapid disease progression before completing the first vaccination cycle, one patient was HLA-A2. Table 1 and were comparable between the groups.
Treatment outcome
The 3 patients with distant metastasis at inclusion had progression-free intervals of 3, 4 and 7 months (Table 1) .
Clinical data are summarized in Table 1 .
Characteristics and distribution of injected DC
Patients in the different groups received on average 12 x 10 6 to 17 x 10 6 DC per vaccination during the first cycle (Table 2) . After maturation, DC of all patients showed a mature phenotype exemplified by high HLA, CD80, CD83 and CD86 expression ( Table 2 ). There was no difference in the amount or maturation status of injected DC between the different groups. Furthermore, there were no significant differences in CCR7 expression between IN and ID injected DC ( Figure 1A ). The distribution of 
KLH-specific immune responses
To investigate whether the differences in distribution after IN and ID vaccination resulted in differences in immunological responses, humoral and cellular responses against the control antigen KLH were measured in peripheral blood of the patients after the first cycle of vaccinations. In all groups, levels of KLH-specific antibodies increased to a similar extent upon vaccination (Figure 2A-D) . KLH-specific T cell proliferation was measured in PBMC of patients after the first cycle of vaccinations by proliferation assay.
KLH-specific proliferation was higher after vaccination than before vaccination in all treatment groups and was induced in all vaccinated patients, including patients that did not show DC migration after the first IN DC vaccination ( Figure 3A-D) . The magnitude of KLH-specific T cell proliferation was similar in all treatment groups. In summary, comparable KLH-specific immune responses are induced irrespective of the route of DC administration or concomitant treatment with IL-2.
Effect of route of administration on tumor antigen-specific responses in DTH-derived T cells
Research. The frequencies of tumor-antigen specific T cells in blood are generally very low. In our previous studies we were often unable to detect tumor antigen-specific T cells in peripheral blood by tetramer staining, while functional tumor antigen-specific T cells were present in biopsies taken from DTH challenges(5;37).
Since the presence of antigen-specific T cells in DTH sites correlates with clinical outcome(5), we monitored tumor antigen-specific responses in lymphocyte cultures from DTH sites. In 32 out of 40 tested patients we were able to retrieve gp100-or tyrosinase-specific T cells from their DTH biopsies as measured by tetramer staining (Supplementary Table 1, Figure 4 
functional T cells. However, after both IN and ID vaccination, co-administration of IL-2 resulted in increased percentages of FOXP3+CD4+ regulatory T cells in peripheral blood (figure 4e), whereas percentages of total CD4+ T cells were unaffected (figure 4f).
Discussion
In this study, we compared intradermal with intranodal injection of a DC vaccine with regard to redistribution of the vaccine to draining lymph nodes and characteristics of the antigen-specific immune responses induced. The results of this study confirm and extend our previous observation that after ID vaccination DC migration never exceeded 4%, whereas after IN injection up to 84% of the injected DC migrated to adjacent lymph nodes(17). Although the median percentage of migrating cells is substantially higher after IN injection, IN injection resulted in large variation in the migratory capacity of DC. Importantly, in 7 IN vaccinated patients, no redistribution of injected DC from the injection depot was found at all, whereas in all ID vaccinated patients at least a small fraction of the injected DC migrated to nearby lymph nodes. In a previous study we found that after IN injection, redistribution to adjacent lymph nodes was only observed when DC were correctly injected into the lymph node, which in that study happened in only ~50% of the cases, despite injection under ultrasound guidance by a highly experienced radiologist(16).
Inadequate delivery of DC may therefore at least partly explain why also in this study in some IN vaccinated patients no DC migration was detected. However, as patients received 4 IN injections in the first vaccination cycle, it is very unlikely that none of the vaccines was delivered correctly into the lymph node, as also suggested by the induction of potent KLH-specific immune responses in all patients. Possibly, the presence of macrophages that have phagocytosed DC may have a negative effect on the immune response, for instance by the secretion of anti-inflammatory cytokines. Lastly, the optimal cell number for DC vaccination has not been firmly established, not for ID, nor for IN vaccination (2) . It is possible that the cell numbers that we used were optimal for ID vaccination but supra-optimal for IN vaccination.
In half of the patients we co-administered IL-2, because of its capacity to stimulate the growth and expansion of antigen-specific cytotoxic T lymphocytes. IL-2 has been used alone or in combination with after the first IL-2 injection, and persisted at least 3 weeks after the last injection. Here we extend these findings: using flow cytometric analysis, we found that that co-administration of IL-2 also significantly increased Treg frequencies in ID vaccinated patients. These findings support the notion that administration of IL-2 can increase Treg frequencies, although in this study we did not observe major differences in the presence of functional antigen-specific T cells between patients vaccinated with or without supplemental IL-2 treatment. Research. 
